- Home
- Primary Care
- Ritlecitinib’s Efficacy and Safety for Treating Vitiligo: A Randomized Clinical Trial Synopsis

3w3 min read
Medical Article
In vitiligo, the autoimmune disorder, melanocytes that are pre-exposed to environmental factors such as oxidative stress are attacked by CD8+ T cells, causing depigmentation in the skin and hair (1,2). This can be treated by triggering repigmentation through janus kinase 3 (JAK3)/ tyrosine protein kinase (TEC) inhibition, which may decrease abnorma

Ritlecitinib’s Efficacy and Safety for Treating Vitiligo: A Randomized Clinical Trial Synopsis
2 Reached
Similar Content

Woman presented with Fever of Unknown Origin
7717 Reached93 Comments19 Likes

How Physicians Should Manage Stress?
35294 Reached152 Comments203 Likes

Rubella Syndrome in Neonate
1396 Reached12 Comments9 Likes

Black Lesion in Old Female
1970 Reached5 Comments11 Likes

Chronic Hyperplastic Candidiasis Of The Oral Mucosa
857 Reached9 Comments11 Likes